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Abstract
Background: Depending on cellular context, p53-inducing agents (such as nutlin-3a) cause different outcomes including
reversible quiescence and irreversible senescence. Inhibition of mTOR shifts the balance from senescence to quiescence. In
cell lines with incomplete responses to p53, this shift may be difficult to document because of a high proportion of
proliferating cells contaminating arrested (quiescent and senescent) cells. This problem also complicates the study of
senescence caused by minimal levels of p21 that are capable to arrest a few cells.
Methodology: During induction of senescence by low levels of endogenous p53 and ectopic p21, cells were co-treated with
nocodazole, which eliminated proliferating cells. As a result, only senescent and quiescent cells remained.
Results and Discussion: This approach revealed that rapamycin efficiently converted nutlin-induced-senescence into
quiescence. In the presence of rapamycin, nutlin-arrested MCF-7 cells retained the proliferative potential and small/lean
morphology. Using this approach, we also unmasked senescence in cells arrested by low levels of ectopic p21, capable to
arrest only a small proportion of HT1080-p21-9 cells. When p21 did cause arrest, mTOR caused senescent phenotype.
Rapamycin and high concentrations of nutlin-3a, which inhibit the mTOR pathway in these particular cells, suppressed
senescence, ensuring quiescence instead. Thus, p21 causes senescence passively, just by causing arrest, while still active
mTOR drives senescent phenotype.
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Introduction
Non-dividing (arrested) cells can be either quiescent or
senescent [1,2]. The senescent phenotype, driven in part by
growth-promoting pathways such as mTOR [3,4] is character-
ized by large/flat cell morphology (hypertrophy), a pro-
inflammatory and hyper-secretory phenotype, beta-Gal-staining
and permanent loss of proliferative potential [5–8]. Proliferative
potential (PP) is not proliferation but a potential to proliferate [9].
Like senescent cells, quiescent cells do not proliferate but, unlike
senescent cells, they retain PP. For example, cells can be arrested
by nutlin-3a, which reversibly induces p53. When nutlin-3a is
removed, quiescent cells re-start proficient proliferation, whereas
senescent cells do not [10].
p53 can both cause and suppress the senescent phenotype. By
causing cell cycle arrest, while not inhibiting cellular mass growth,
p53 can cause senescence [11]. When p53 inhibits mTOR, it
converts senescence into quiescence [11]. In several cancer cell
lines, nutlin-3a failed to inhibit mTOR and some cells acquired
senescent morphology [12]. However, senescent cells co-existed
with proliferating cells that were not arrested by nutlin-3a. These
proliferating cells rapidly overwhelmed the culture. To investigate
proliferative potential (PP) of arrested cells, it seems prudent to
eliminate all proliferating (nutlin-nonresponsive) cells. A similar
problem complicates the study of p21-induced senescence. To
observe whether cells retain the proliferative potential, one needs
to induce p21 and then to switch it off. In a useful model
(HT1080-p21-9 cells), HT-1080 cells express ectopic p21,
inducible by IPTG. IPTG-induced p21 rapidly arrests cells, which
become senescent in 3-4 days. By increasing the concentration of
IPTG, one can increase levels of p21 to achieve senescence in all
cells. However, at such high levels, p21 may exert other effects
besides cell cycle arrest. It was suggested that p21 actively induces
the senescent program, independently from its ability to cause
arrest. Alternatively, p21 causes senescence passively, just by
causing arrest (while still active growth-promoting pathways (such
as mTOR) drive senescent phenotype). To distinguish between the
two models, we wish to determine whether minimal levels of p21
(capable to arrest a small proportion of cells) still cause senescence
in arrested cells. For that, we need to eliminate cells that are not
arrested by p21.
Our unrelated studies suggested a simple solution, given that cell
cycle arrest protects normal cells from chemotherapy with mitotic
inhibitors [13]. Mitotic inhibitors such as nocodazole killed only
proliferating cells, whereas both senescent and quiescent HT1080-
p21-9 cells were spared [14].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26126Results
Treatment of nutlin-arrested cells with nocodazole
In MCF-7 cells, in agreement with our previous report [12],
nutlin-3a caused senescent morphology in some but not all cells
(Fig. 1A) and did not decrease levels of pS6, a marker of mTOR
activity (Fig. 1B). Given that only a small proportion of cells
become senescent, we also measured mTOR activity in individual
cells by immunostaining (Fig. 1C). Most nutlin-3a-treated cells
were positive for pS6; including all cells with a large, flat
(senescent) morphology (Fig. 1C). Rapamycin blocked pS6
(Fig. 1B) and prevented senescent morphology in nutlin-treated
cells (Fig. 1A). However, it was difficult to test proliferative
potential (PP) of nutlin-arrested cells because still proliferating cells
overwhelmed the cell culture. This masks potentially irreversible
arrest in arrested cells.
To eliminate cells that still proliferate in the presence of nutlin-
3a, we co-treated the culture with nocodazole (Fig. 2). While
eliminating proliferating cells (Noc), nocodazole spared quiescent
(Fig. 2: Nu+Noc+R) and senescent (Fig. 2: Nut+Noc) cells (Fig. 2A).
Rapamycin prevented senescent morphology in nutlin-arrested
cells (Fig. 2A). These cells retained PP and resumed proliferation
(Fig. 2B). In other words, rapamycin shifted senescence to
quiescence. Like senescent cells, quiescent cells did not proliferate
and therefore were spared from nocodazole. Unlike senescent
cells, however, quiescent cells retained PP and formed colonies
after all drugs were washed out (Fig. 2C).
Treatment of IPTG-treated cells with nocodazole
In a dose-dependent manner (with a maximal effect at 10 mg/
ml or 50 mM), IPTG induces p21 and causes cell cycle arrest in
HT1080-p21-9 cells [15,16]. When 10 mg/ml IPTG was washed
out after 3 days, cells could not resume proliferation because they
died in mitosis [16]. As shown here, only about 5% of cells treated
with 5–50 mg/ml IPTG formed colonies upon removal of IPTG
(Fig. 3A). The number of colonies was progressively increased,
when concentration of IPTG was decreased to 1.25 mg/ml,
probably either because the arrest was reversible or because cells
simply were not arrested by low concentrations of IPTG in the first
place. In the presence of 1.25 mg/ml IPTG, some cells acquired
senescent morphology (Fig. 4). But do these cells retain
proliferative potential? Treatment with rapamycin did not allow
us to answer this question clearly. Whereas at high concentrations
of IPTG, rapamycin increased a number of colonies 10 fold
(prevention of senescence), there was no detectable change in
number of colonies at 1.25 mg/ml IPTG (Fig. 3B). At low
concentrations of IPTG, the effect of rapamycin became less
evident (Fig. 3B). Either low concentrations of IPTG caused
quiescence rather than senescence or simply the culture was
overwhelmed by proliferating cells, which did not respond to
IPTG.
By eliminating non-arrested cells, nocodazole revealed the status
of arrested cells (Fig. 3 C-D). At 0-2.5 mg/ml IPTG without
rapamycin, only cells with senescent morphology survived
nocodazole (Fig. 3C) and only a few colonies were formed.
Rapamycin prevented the senescent morphology (Fig. 4) and also
increased a number of colonies at all concentrations of IPTG,
proportionally to a number of IPTG-arrested cells (Fig 3D). We
extended treatment with nocodazole to 4 days (Fig. S1). At all
concentrations of IPTG, including 1.25 mg/ml, cells poorly
proliferated after removal of drugs (IPTG+Noc). Rapamycin
increased cell numbers at all concentrations of IPTG (Fig. S1). We
conclude that IPTG-arrested cells were senescent at all concen-
trations of IPTG.
We have previously shown that nutlin-3a suppressed senescence
caused by high concentrations of IPTG [10,11]. Here we
investigated whether nutlin-3a would also suppress senescence
caused by low concentrations of IPTG. Cells arrested (and thus
protected from nocodazole) by 2 mg/ml IPTG did not retain
proliferative potential and did not form colonies, when these drugs
were removed (Fig. 5). In such IPTG-arrested cells, nutlin-3a
preserved proliferative potential (Fig. 5).
Figure 1. Rapamycin prevents nutlin-induced senescent morphology in MCF-7 cells. A. MCF7 cells were plated at 5000 or 10000/well in 12
well plates, allowed to attach and then were either pretreated with 500 nM rapamycin (R), or left untreated in complete medium (control). The next
day, 5 mM nutlin-3a was added. After 5 days, cells were stained for beta-Gal and microphotographed (bar -50 micron). B. MCF7 cells were treated as
indicated for 24 hr, and immunoblot was performed as described in Methods; C- control, N- 5 mM Nutlin 3a, R- 500 nM rapamycin. C. MCF7 cells were
seeded in on-slide chambers at 500 cells/well with 5 mM Nutlin-3a After 4 days cells were fixed and stained for pS6; nuclei were visualized by
counterstaining with Hoechst 33258 (DAPI). Photos were taken at 20x.
doi:10.1371/journal.pone.0026126.g001
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nutlin-3a (Nut) or 5 mM nutlin-3a + 10 nM rapamycin (Nut+R). The next day, 200 nM nocodazole was added as indicated (Noc) in the right panel. After
4 days live cells were microphotographed. B. MCF-7 cells were treated as described in panel A. After 4 days with nocodazole 1 set of cells was
counted (at wash) and 2
nd set was washed and incubated for 6 days in drug free-medium and then live cells were microphotographed (C) and
counted (after 6 days). Results are shown as cell numbers per well. C. Microphotographs of MCF-7 cells treated as described in B.
doi:10.1371/journal.pone.0026126.g002
Figure 3. Rapamycin suppresses senescence caused by low concentrations of IPTG. HT1080-p21-9 cells were plated in 6-well plates at
5000 per well with a range of IPTG concentrations in the absence (A and C) or in the presence of 500 nM rapamycin (+Rap) (B and D). Next day 200
nM Nocodazole was added to half of the wells (right panel - +Noco). After 3 days, cells were washed and incubated in drug-free medium for 7 days.
Then colonies were stained with crystal violet. Note: In the absence of any drugs, cells overgrew and could not be stained (overgrown).
doi:10.1371/journal.pone.0026126.g003
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Here we extended the model that cellular senescence is caused
by active nutrient-sensing and growth-promoting pathways such as
mTOR, when the cell cycle is blocked by either p21 or p53.
Regardless of whether arrest is induced by p21 or p53, it is the
status of the mTOR pathway that in part determined senescence.
In our previous work, it was crucial to arrest all cells. There were 2
limitations. First, in some cell lines, the arrest could not be
achieved in all cells, unless toxic concentrations of p53-inducing
agents were used. Second, in order to arrest all cells, ectopic p21
was used at super-physiological levels. Here we used low levels of
p53 and p21 and achieved arrest in all cells, simply by eliminating
non-arrested cells with nocodazole.
First, we found that at low concentrations of IPTG, while most
cells were proliferating, the arrested cells were senescent. This
supports the notion that the ‘‘senescent state’’ borders with the
‘‘growth state’’ [17]. Second, rapamycin shifted senescence to
quiescence. Third, rapamycin did not force proliferation in the
presence of IPTG but simply preserved PP. Fourth, senescent
morphology (such as hypertrophy and beta-Gal staining, enlarged
nucleoli) correlated with loss of PP. Fifth, this provides a model to
study a pure senescent cell population. In brief, this work suggests
that the nature of cell cycle arrest (whether it is caused by high or
low levels of p21 and p53) does not determine senescent
phenotype. Rather it is active growth-promoting mTOR-centered
pathways that drive senescence in arrested cells.
Materials and Methods
Cell lines and reagents
HT1080-p21-9 cells, derived from HT1080 human fibrosarco-
ma cells (ATCC, Manassas, VA), were kindly provided by Dr. Igor
Roninson and previously described [4,7,15,16]. In these cells p21
expression can be turned on or off using a physiologically neutral
agent isopropyl-thio-galactosidase (IPTG). MCF-7 breast carcino-
ma cell line was obtained from ATCC (Manassas, VA). MCF-7,
breast cancer cell line was cultured in high-glucose DMEM (plus
pyruvate) with 10% FBS. HT1080-p21-9 cells were cultured in
high-glucose DMEM without puruvate supplemented with FC2
serum (HyClone FetalClone II from Thermo Scientific, Logan,
Utah). In HT1080-p21-9 cells, p21 expression can be turned on or
Figure 4. Co-treatment with nocodazole reveals the gerosuppressive effect of rapamycin at low concentrations of IPTG. HT1080-p21-
9 cells were plated in 12 well plates at 20,000 cells per well and incubated with 1.25 mg/ml IPTG with or without 200 nM nocodazole (Noc) and in the
presence or absence of 500 nM rapamycin (Rap) as indicated. After 3 days, cells were stained for beta-Gal and microphotographed. Bar - 50 micron.
doi:10.1371/journal.pone.0026126.g004
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obtained from LC Laboratories (MA, USA) and dissolved in
DMSO as 5 mM solution. Nutlin-3a and nocodazole were
purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in
DMSO as 10 mM and 6 mM stocks, respectively. IPTG (Invitro-
gen) was dissolved in water as 50 mg/ml stock solution and used in
cell culture at a final concentration of 1.25-50 mg/ml.
Immunoblot analysis
Whole cell lysates were prepared using boiling lysis buffer
(1%SDS, 10 mM Tris.HCl, pH 74.). Equal amounts of proteins
were separated on 10% or gradient polyacrylamide gels and
transferred to nitrocellulose membranes. The following antibodies
were used: mouse anti-p53 (Ab-6) from Oncogene, mouse anti-p21
from BD Biosciences; rabbit anti-actin from Sigma-Aldrich; rabbit
anti-phospho-S6 (Ser235/236) from Cell Signaling Biotechnology.
Secondary anti-rabbit and anti-mouse HRP conjugated antibodies
were from Cell Signaling Biotechnology. Signals were visualized
using ECL chemilumenescence kit from Pierce.
SA-b-Gal staining
Beta-Gal staining was performed using Senescence-galactosi-
dase staining kit (Cell Signaling Technology) according to
manufacturer’s protocol. Cells were incubated at 37uC until
beta-gal staining becomes visible. Development of color was
detected under light microscope [12].
Proliferative potential
Proliferative potential was determined as described in detail in
Figure legends.
Immunostaining
Cells were fixed in 4% paraformaldehyde for 15 min, washed in
PBS and permeabilized in 0.5% Triton X-100/PBS for 30 min at
RT, blocked with 3% BSA/PBS for 30 min at RT followed by
consequent incubations with 1:200 dilution of rabbit anti-phospho
S6 (Ser 235/236) antibody in 3% BSA/PBS for 1 h and secondary
donkey anti-rabbit Alexaflour 594 antibody (Invitrogen) (1:500) for
30 min. After washes cells were counterstained with Hoechst
33258 1 mg/ml in PBS for 15 min and mounted with antifade
reagent Fluoromount G (Invitrogen).
Colony formation assay
Cells in wells were fixed and stained with 1.0% crystal violet in
10% ethanol.
Supporting Information
Figure S1 Co-treatment with nocodazole reveals the
gerosuppressive effect of rapamycin at low concentra-
tions of IPTG. HT1080-p21-9 cells were plated in 48-well plates
and treated with indicated concentrations of IPTG in the absence
(blue bars) or presence of rapamycin (red bars). Then 200 nM
nocodazole was added and cells were cultured for 4 days. Cells
were washed and incubated in drug-free medium for 7 days and
the number of viable cells were determined by Celltiter blue
reagent (Promega).
(TIF)
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